Direkt zum Inhalt
Symbolfoto: Das AIT ist Österreichs größte außeruniversitäre Forschungseinrichtung

Researcher Profile

Priv.-Doz. Dipl.-Ing. Dr. Winfried Neuhaus

Priv.-Doz. Dipl.-Ing. Dr. Winfried Neuhaus


Principal Scientist


Health & Bioresources

Competence Unit

Molecular Diagnostics




+43 50550 4450


Giefinggasse 4, 1210 Vienna


Field: Molecular Diagnostics

Main Research: Biological Barriers


Biological barriers in health and disease, most work on blood-brain barrier, kidney and lung epithelia.
Development of in vitro models under static as well as under dynamic flow systems; comprehensive characterization of barrier models with regard to the paracellular, transport and metabolic barrier; disease models with a focus on qualification and cross-validation to in vivo models (e.g. stroke, traumatic brain injury, Alzheimers disease, chronic inflammation), application for drug transport and elucidation of transport mechanisms, disease models and investigation of underlying mechanisms, cross-talk between barrier forming cells and their microenvironment, influence of shear stress, application of disease models for the development of therapeutic strategies and their evaluation in according in vivo models; development of biological barriers; species differences of biological barriers; blood-saliva barrier including epithelia of oral mucosa and salivary glands; biological barriers and biomarkers; biomarker's relevance for disease’s etiology and subsequent clinical applicability.

  • 2010-2016: Researcher & Priv.-Doz.
    University Hospital of Würzburg / Germany
  • 2015-2016: Scientist
    Institute of Medical Genetics, Medical University of Vienna / Austria
  • 2013-2016: Principal Investigator
    Department of Pharmaceutical Chemistry, University of Vienna / Austria
  • 2008-2009: Research Group Leader
    PharmaCon GmbH / Austria
  • 2008: Inits Award
  • 2008: ZET Award


  • A novel tool to characterize paracellular transport: the APTS-dextran ladder
    Author(s): Neuhaus W, Bogner E, Wirth M, Trzeciak J, Lachmann B, Gabor F, Noe CR
    Journal: Pharm Res (2006)
  • Lung endothelial cells strengthen, but brain endothelial cells weaken barrier properties of a human alveolar epithelium cell culture model
    Author(s): Neuhaus W, Samwer F, Kunzmann S, Muellenbach RM, Wirth M, Speer CP, Roewer N, Förster CY
    Journal: Differentiation (2012)
  • The effects of colloid solutions on renal proximal tubular cells in vitro.
    Author(s): Neuhaus W, Schick MA, Bruno RR, Schneiker B, Förster CY, Roewer N, Wunder C
    Journal: Anesth Analg (2012)
  • Inhibition of proteasomal glucocorticoid receptor degradation restores dexamethasone-mediated stabilization of the blood-brain barrier after traumatic brain injury
    Author(s): Thal SC, Schaible EV, Neuhaus W, Scheffer D, Brandstetter M, Engelhard K, Wunder C, Förster CY.
    Journal: Crit Care Med (2013)
  • Transport rankings of non-steroidal antiinflammatory drugs across blood-brain barrier in vitro models
    Author(s): Novakova I, Subileau EA, Toegel S, Gruber D, Lachmann B, Urban E, Chesne C, Noe CR, Neuhaus W
    Journal: PLoS One (2014)
  • The pivotal role of astrocytes in an in vitro stroke model of the blood-brain barrier
    Author(s): Neuhaus W, Gaiser F, Mahringer A, Franz J, Riethmüller C, Förster C
    Journal: Front Cell Neurosci (2014)
  • The blood-brain barrier as a target in traumatic brain injury treatment
    Author(s): Thal SC, Neuhaus W
    Journal: Arch Med Res. (2014)
  • Multiple Antenatal Dexamethasone Treatment Alters Brain Vessel Differentiation in Newborn Mouse Pups
    Author(s): Neuhaus W, Schlundt M, Fehrholz M, Ehrke A, Kunzmann S, Liebner S, Speer CP, Förster CY
    Journal: PLoS One (2015)
  • Establishment of a Human Blood-Brain Barrier Co-culture Model Mimicking the Neurovascular Unit Using Induced Pluri- and Multipotent Stem Cells
    Author(s): Appelt-Menzel A, Cubukova A, Guenther K, Edenhofer F, Piontek J, Krause G, Stüber T, Walles H, Neuhaus W*, Metzger M* (*=Co-senior authors)
    Journal: Stem Cell Reports (2017)
  • Reversible opening of the blood-brain barrier by claudin-5-binding variants of Clostridium perfringens enterotoxin's claudin-binding domain
    Author(s): Neuhaus W, Piontek A, Protze J, Eichner M, Mahringer A, Subileau EA, Lee IF M, Schulzke JD, Krause G, Piontek J
    Journal: Biomaterials, 161 (2018) ; 129-143
  • Plasminogen activator inhibitor-1 augments damage by impairing fibrinolysis after traumatic brain injury
    Author(s): Griemert EV, Schwarzmaier SM, Hummel R, Gölz C, Yang D, Neuhaus W, Burek M, Förster CY, Petkovic I, Trabold R, Plesnila N, Engelhard K, Schäfer MK, Thal SC
    Journal: Annals of Neurology, 85 (2019) ; 667-680
  • Oxygen management at the microscale: A functional biochip material with long-lasting and tunable oxygen scavenging properties for cell culture applications
    Author(s): Sticker D, Rothbauer M, Ehgartner J, Steininger C, Liske O, Liska R, Neuhaus W, Mayr T, Haraldsson T, Kutter JP, Ertl P.
    Journal: ACS Applied Materials and Interfaces (2019) ; 1-9
  • In-vitro assays for assessing BBB permeability: artificial membrane and cell culture models;
    Blood-Brain Barrier in Drug Discovery: Optimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects

    Author(s): A. Avdeef, M.A. Deli, W. Neuhaus
    Publisher: Whiley-VCH Verlag GmbH & Co. KGaA; 2015; 188-237
    Series: Li & Kerns
  • Novel strategies to restore blood-brain barrier integrity after brain injury;
    Blood Brain Barrier: New Research

    Author(s): W. Neuhaus, M. Burek, C. Wunder, C.Y. Förster
    Publisher: Nova Science; 2012; 145-172
    Series: P.A. Montenegro, S.M.
  • Transport at the Blood-Brain Barrier;
    Transporters as drug carriers

    Author(s): W. Neuhaus, C.R. Noe
    Publisher: Whiley-VCH Verlag GmbH & Co. KGaA; 2009; 263-298
    Series: G.F. Ecker, P. Chiba

Further Information